BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35462848)

  • 1. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
    Zheng Y; Wu R; Wang X; Yin C
    Front Public Health; 2022; 10():860381. PubMed ID: 35462848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 3. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INHBA is a prognostic predictor for patients with colon adenocarcinoma.
    Li X; Yu W; Liang C; Xu Y; Zhang M; Ding X; Cai X
    BMC Cancer; 2020 Apr; 20(1):305. PubMed ID: 32293338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
    Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
    Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
    Wang H; Wang W; Wang Z; Li X
    Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma.
    Yang M; He H; Peng T; Lu Y; Yu J
    Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma.
    Zhao F; Liu Y; Gu X; Zhang B; Song C; Cui B
    J BUON; 2021; 26(4):1252-1259. PubMed ID: 34564978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel glycolysis-related gene signature for predicting the survival of patients with colon adenocarcinoma.
    Yi K; Wu J; Tang X; Zhang Q; Wang B; Wang F
    Scand J Gastroenterol; 2022 Feb; 57(2):214-221. PubMed ID: 34644216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma.
    Miao YD; Kou ZY; Wang JT; Mi DH
    World J Clin Cases; 2021 Oct; 9(29):8671-8693. PubMed ID: 34734046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of Gene Expression Profiles Identifies a
    Chen Z; Chen M; Xue Z; Zhu X
    Cancer Biother Radiopharm; 2021 Oct; 36(8):693-704. PubMed ID: 34520234
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a prognostic model for personalized prediction of colon adenocarcinoma (COAD) patient outcomes using methylation-driven genes.
    Chen D; Zhang B; Kang K; Li L; Liao Y; Qing S; Di Y
    J Appl Genet; 2023 Dec; 64(4):713-721. PubMed ID: 37589877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.